We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Combined Automated Blood Tests Estimate Prostate Cancer Probability

By LabMedica International staff writers
Posted on 19 Apr 2010
Three automated blood tests combined into one index estimates a man's probability of having prostate cancer found on biopsy.

A new prostate disease marker, p2prostate-specific antigen (p2PSA), and the Prostate Health Index (phi), significantly improve the specificity of prostate cancer biomarker assessment. More...


Serum Beckman Coulter (Nyon, Switzerland) phi is a multivariate index incorporating prostate-specific antigen (PSA), free PSA, and proPSA concentrations into a single result. This enables medical professionals to estimate the probability of cancer in men aged 50 and older with total PSA in the 2.0-10.0 ng/mL range and a nonsuspicious digital rectal examination (DRE).

proPSA is a novel serum marker strongly associated with prostate cancer and delivers added specificity to PSA. As a result, phi contributes to reduce significantly the number of negative biopsies resulting from suspicious PSA or free PSA results.

Beckman Coulter phi is a composite score of Access Hybritech PSA, free PSA and the new p2PSA assay, which measures the isoform proPSA.

A new website introduced by Beckman Coulter, was designed to encourage dialogue between patients, physicians, and laboratory professionals. It provides guidance and education to all parties in order to foster confident prostate biopsy decision-making. The website (please see related links below) provides links to credible medical resources, the latest unbiased scientific studies, and details the benefits of the latest blood test, which can noninvasively identify patients who are most likely to have a negative prostate biopsy.

Related Links:

Beckman Coulter

Prostate Health Index



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Automated Urinalysis Solution
UN-9000
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.